Light Collimation and Focussing by a Thin Flat Metallic Slab

We present experimental and theoretical work showing that a flat metallic slab can collimate and focus light impinging on the slab from a punctual source. The effect is optimised when the radiation is around the bulk, not at the surface, plasma frequency. And the smaller the imaginary part of the permittivity is, the better the collimation. Experiments for Ag in the visible as well as calculations are presented. We also discuss the interesting case of the Aluminium whose imaginary part of the permittivity is very small at the plasma frequency in UV radiation. Generalization to other materials and radiations are also discussed.Comment: 6 pages, 3 figures. To be published on Optics Lette

Effect of extended short-circuiting in proton exchange membrane fuel cells

Short-circuiting is regularly utilized in Proton Exchange Membrane Fuel Cells (PEMFCs) to reverse short-term reversible catalyst degradation. However, do these improvements in fuel cell performance and durability still exist after extended operation? We provide an answer to this question by comparing the performance and durability of a PEMFC under open-circuit voltage (OCV) and a commercial short-circuiting protocol, against a PEMFC under OCV without short-circuiting for the same extended period (∼144 h). The experimental results demonstrate the detrimental effect of extended short-circuiting on the durability of the catalyst and the performance of the fuel cell. Electrochemically active surface area losses reach ∼46% for the short-circuiting case, compared to only ∼18% losses for the OCV without short-circuiting. TEM and XPS measurements are employed to monitor the morphological changes of the catalyst layer, revealing that Ostwald ripening, carbon corrosion, and Pt migration and precipitation into the polymer membrane are the main degradation mechanisms of the cathode catalyst layer. At the end of PEMFC operation, XPS measurements reveal that only ∼0.1% (atomic) of Pt remains on the surface of the cathode catalyst layer after OCV with short-circuiting, compared to the initial ∼0.4% Pt of the unused cathode MEA and ∼0.3% Pt for the cathode MEA after OCV without short-circuiting. These results show that short-circuiting can cause facile degradation of the catalyst layer and significant decrease in fuel cell performance, rendering this technique non-beneficial for extended operation

Chromatic dispersion mapping by sensing the power distribution of four-wave mixing along the fiber using Brillouin probing

A new method for chromatic dispersion mapping in optical fibers is presented. It is based on measuring the CW four-wave mixing distribution created by two beams along the fiber using a Brillouin-OTDA. Experimental results demonstrate the feasibility of the techniqu

Brillouin optical time-domain analysis over a 240 km-long fiber loop with no repeater

22nd International Conference on Optical Fiber Sensors (OFS2012), Beijing, China, October 14, 2012In this paper we combine the use of optical pulse coding and seeded second-order Raman amplification to extend the\ud sensing distance of Brillouin optical time-domain analysis (BOTDA) sensors. Using 255-bit Simplex coding, the power\ud levels of the Raman pumps and the Brillouin pump and probe signals were adjusted in order to extend the real physical\ud sensing distance of a BOTDA sensor up to 120 km away from the sensor interrogation unit, employing a 240-km long\ud loop of standard single-mode fiber (SSMF) with no repeater. To the best of our knowledge, this is the first time that\ud distributed measurements are carried out over such a long distance with no active device inserted into the entire sensing\ud loop, constituting a considerable breakthrough in the field

Nonlinear absorption of InN/InGaN multiple-quantum-well structures at optical telecommunication wavelengths

We report on the nonlinear optical absorption of InN/ InxGa 1-x N (x=0.8,0.9) multiple-quantum-well structures characterized at 1.55 μm by the Z-scan method in order to obtain the effective nonlinear absorption coefficient (α2) of the samples at high repetition rate. Saturable absorption is observed for the sample with x=0.9, with an effective α2 ∼-9× 103 cm/GW for the studied optical regime. For lower In content in the barrier, reverse saturable absorption is observed, which is attributed to two-photon absorption. © 2011 American Institute of Physics.Peer Reviewe

Basal oxidation of conserved cysteines modulates cardiac titin stiffness and dynamics

Titin, as the main protein responsible for the passive stiffness of the sarcomere, plays a key role in diastolic function and is a determinant factor in the etiology of heart disease. Titin stiffness depends on unfolding and folding transitions of immunoglobulin-like (Ig) domains of the I-band, and recent studies have shown that oxidative modifications of cryptic cysteines belonging to these Ig domains modulate their mechanical properties in vitro. However, the relevance of this mode of titin mechanical modulation in vivo remains largely unknown. Here, we describe the high evolutionary conservation of titin mechanical cysteines and show that they are remarkably oxidized in murine cardiac tissue. Mass spectrometry analyses indicate a similar landscape of basal oxidation in murine and human myocardium. Monte Carlo simulations illustrate how disulfides and S-thiolations on these cysteines increase the dynamics of the protein at physiological forces, while enabling load- and isoform-dependent regulation of titin stiffness. Our results demonstrate the role of conserved cysteines in the modulation of titin mechanical properties in vivo and point to potential redox-based pathomechanisms in heart disease.This work was supported by the Ministerio de Ciencia e Innovación grants BIO2014-54768-P, BIO2017-83640-P, RYC-2014-16604 to JAC and PGC2018-097019-B-I00 to JV, the Regional Government of Madrid grants S2018/NMT-4443 and PEJ16/MED/TL-1593 to JAC and the Instituto de Salud Carlos III (Fondo de Investigación Sanitaria grant PRB3 (PT17/0019/0003- ISCIII-SGEFI /ERDF, ProteoRed), and “la Caixa” Banking Foundation (project code HR17-00247) to JV. We acknowledge funding from the European Research Area Network on Cardiovascular Disease through grant MINOTAUR to SS (The Austrian Science Fund – FWF, I3301) and JAC (ISCIII-AC16/00045). The CNIC is supported by ISCIII, the Ministerio de Ciencia e Innovación and the Pro CNIC Foundation, and was a Severo Ochoa Center of Excellence (SEV-2015-0505). IMM was the recipient of a CNIC-ACCIONA Masters Fellowship and holds a fellowship from “La Caixa” Foundation (ID 100010434, fellowship code LCF/BQ/DR20/11790009). CSC is the recipient of an FPI-SO predoctoral fellowship BES-2016-076638. We thank Wolfgang A. Linke and Pablo García-Pavía for critical feedback. We are also thankful for the insights of three anonymous reviewers.S

Líneas de investigación experimentales del grupo de dinámica no lineal y fibras ópticas del Instituto de Óptica "Daza de Valdes del CSIC"

Se presenta y describen las líneas de trabajo experimentales que se vienen cultivando en el Grupo de investigación en Dinámica no Lineal y Fibras ópticas, recientemente creado en el Instituto de Óptica del CSIC. We present the experimental lines developed in last years in the Nonlinear Dynamics and Fiber Optics Group (NDFO) of the Optics Institute "Daza de Valdés" (IO-CSIC)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research